These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15719330)

  • 21. Clinical outcomes associated with albuminuria in central Australia: a cohort study.
    Ritte R; Luke J; Nelson C; Brown A; O'Dea K; Jenkins A; Best JD; McDermott R; Daniel M; Rowley K
    BMC Nephrol; 2016 Aug; 17(1):113. PubMed ID: 27495237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
    Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
    Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The estimated costs and savings of medical nutrition therapy: the Medicare population.
    Sheils JF; Rubin R; Stapleton DC
    J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness of stroke care in Aboriginal and non-Aboriginal patients: an observational cohort study in the Northern Territory of Australia.
    Zhao Y; Guthridge S; Falhammar H; Flavell H; Cadilhac DA
    BMJ Open; 2017 Oct; 7(10):e015033. PubMed ID: 28982808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homocysteine, renal disease and cardiovascular disease in a remote Australian Aboriginal community.
    McDonald S; Maguire G; Duarte N; Wang XL; Hoy W
    Intern Med J; 2005 May; 35(5):289-94. PubMed ID: 15845111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
    Schädlich PK; Brecht JG; Brunetti M; Pagano E; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2001; 19(5 Pt 1):497-512. PubMed ID: 11465309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
    Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
    Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.
    Carroll CA; Coen MM; Rymer MM
    Clin Ther; 2003 Apr; 25(4):1248-61. PubMed ID: 12809971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of an Aboriginal community-based renal disease management program incorporating point of care testing for urine albumin:creatinine ratio.
    Shephard MD; Allen GG; Paizis K; Barbara JA; Batterham M; Vanajek A
    Rural Remote Health; 2006; 6(4):591. PubMed ID: 17022724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enalapril to lisinopril: economic impact of a voluntary angiotensin-converting enzyme-inhibitor substitution program in a staff-model health maintenance organization.
    McDonough KP; Weaver RH; Viall GD
    Ann Pharmacother; 1992 Mar; 26(3):399-404. PubMed ID: 1313320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
    Alexander CM; Lyle PA; Keane WF; Carides GW; Zhang Z; Shahinfar S
    Kidney Int Suppl; 2004 Nov; (92):S115-7. PubMed ID: 15485403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.
    Laba TL; Hayes A; Lo S; Peiris DP; Usherwood T; Hillis GS; Rafter N; Reid CM; Tonkin AM; Webster R; Neal BC; Cass A; Patel A; Rodgers A; Jan S
    Med J Aust; 2014 Dec; 201(11):671-3. PubMed ID: 25495315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Grover SA; Coupal L; Zowall H
    Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.